Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/23006
Title: Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Authors: 
Mesh: 
Issue Date: Feb-2015
Citation: Oncologist.2015 Feb;(20)2:111-2
Abstract: The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily dose but a similar cumulative dose in an attempt to reduce the severity of adverse events (AEs) while maintaining efficacy.
PMID: 25601966
URI: https://hdl.handle.net/20.500.12530/23006
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC4319639.pdf665.98 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.